Source:http://linkedlifedata.com/resource/pubmed/id/18440447
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2008-4-28
|
| pubmed:abstractText |
Methylnaltrexone, a peripherally-acting quaternary opioid antagonist, is an investigational treatment for opioid-induced constipation in patients with advanced illness. This randomized, parallel-group, repeated dose, dose-ranging trial included a double-blind phase for one week followed by an open-label phase for a maximum of three weeks. Opioid-treated patients with advanced illness who met criteria for opioid-induced constipation despite laxative therapy were potentially eligible. Double-blind treatment occurred on Days 1, 3, and 5; open-label therapy could be administered as often as every other day. The initial dose range of 1mg, 5mg, or 12.5mg was extended by adding a 20mg group during the study while still maintaining the double blind; the initial open-label dose of 5mg could be titrated. The primary outcome was a laxation response within four hours after the first dose. Thirty-three patients received at least one dose of methylnaltrexone. Only one of 10 patients (10%) who received the 1mg dose experienced laxation within four hours of dosing. The median time to laxation was >48 hours for the 1mg dose group, compared to 1.26 hours for all patients receiving >or=5mg (P=0.0003). There was no apparent dose-response above 5mg. Most adverse events were related to the gastrointestinal system, were mild, and did not lead to discontinuation. In conclusion, methylnaltrexone relieved opioid-induced constipation at doses >or=5mg in patients with advanced illness, and did not reduce analgesia or cause opioid withdrawal symptoms.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/Naltrexone,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotic Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Quaternary Ammonium Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/methylnaltrexone
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0885-3924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
35
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
458-68
|
| pubmed:meshHeading |
pubmed-meshheading:18440447-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:18440447-Adult,
pubmed-meshheading:18440447-Aged,
pubmed-meshheading:18440447-Aged, 80 and over,
pubmed-meshheading:18440447-Analgesics, Opioid,
pubmed-meshheading:18440447-Diarrhea,
pubmed-meshheading:18440447-Dose-Response Relationship, Drug,
pubmed-meshheading:18440447-Double-Blind Method,
pubmed-meshheading:18440447-Female,
pubmed-meshheading:18440447-Humans,
pubmed-meshheading:18440447-Injections, Subcutaneous,
pubmed-meshheading:18440447-Male,
pubmed-meshheading:18440447-Middle Aged,
pubmed-meshheading:18440447-Naltrexone,
pubmed-meshheading:18440447-Narcotic Antagonists,
pubmed-meshheading:18440447-Neoplasms,
pubmed-meshheading:18440447-Pain,
pubmed-meshheading:18440447-Pain Measurement,
pubmed-meshheading:18440447-Quaternary Ammonium Compounds,
pubmed-meshheading:18440447-Terminal Care
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.
|
| pubmed:affiliation |
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA. rporteno@chpnet.org
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|